Genmab Statistics

Total Valuation

Genmab has a market cap or net worth of GBP 10.87 billion. The enterprise value is 9.02 billion.

Market Cap	10.87B
Enterprise Value	9.02B

Important Dates

The next estimated earnings date is Friday, February 14, 2025.

Earnings Date	Feb 14, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-1.23%
Shares Change (QoQ)	-1.51%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	62.85M

Valuation Ratios

The trailing PE ratio is 20.72.

PE Ratio	20.72
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	5.41
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.44, with an EV/FCF ratio of 12.30.

EV / Earnings	17.19
EV / Sales	4.01
EV / EBITDA	11.44
EV / EBIT	12.13
EV / FCF	12.30

Financial Position

The company has a current ratio of 5.17, with a Debt / Equity ratio of 0.03.

Current Ratio	5.17
Quick Ratio	5.15
Debt / Equity	0.03
Debt / EBITDA	0.14
Debt / FCF	0.15
Interest Coverage	149.16

Financial Efficiency

Return on equity (ROE) is 14.92% and return on invested capital (ROIC) is 12.66%.

Return on Equity (ROE)	14.92%
Return on Assets (ROA)	10.95%
Return on Capital (ROIC)	12.66%
Revenue Per Employee	840,368
Profits Per Employee	199,124
Employee Count	2,204
Asset Turnover	0.53
Inventory Turnover	10.98

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -22.80% in the last 52 weeks. The beta is 0.86, so Genmab's price volatility has been lower than the market average.

Beta (5Y)	0.86
52-Week Price Change	-22.80%
50-Day Moving Average	1,518.96
200-Day Moving Average	1,747.32
Relative Strength Index (RSI)	52.27
Average Volume (20 Days)	36,761

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Genmab had revenue of GBP 2.21 billion and earned 524.69 million in profits. Earnings per share was 8.06.

Revenue	2.21B
Gross Profit	2.13B
Operating Income	732.36M
Pretax Income	733.03M
Net Income	524.69M
EBITDA	764.94M
EBIT	732.36M
Earnings Per Share (EPS)	8.06

Full Income Statement

Balance Sheet

The company has 1.93 billion in cash and 110.14 million in debt, giving a net cash position of 1.82 billion.

Cash & Cash Equivalents	1.93B
Total Debt	110.14M
Net Cash	1.82B
Net Cash Per Share	n/a
Equity (Book Value)	3.56B
Book Value Per Share	56.08
Working Capital	2.13B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 751.10 million and capital expenditures -17.85 million, giving a free cash flow of 733.25 million.

Operating Cash Flow	751.10M
Capital Expenditures	-17.85M
Free Cash Flow	733.25M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 96.10%, with operating and profit margins of 33.07% and 23.69%.

Gross Margin	96.10%
Operating Margin	33.07%
Pretax Margin	33.10%
Profit Margin	23.69%
EBITDA Margin	34.54%
EBIT Margin	33.07%
FCF Margin	33.11%

Dividends & Yields

Genmab does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	1.23%
Shareholder Yield	1.23%
Earnings Yield	4.83%
FCF Yield	6.74%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Genmab has an Altman Z-Score of 12.28.

Altman Z-Score	12.28
Piotroski F-Score	n/a